

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7171676

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
EDMUNDO BRITO DE LA FUENTE	07/09/2019
ERICKA PESTANA	07/18/2019
STEPHANIE REICHART	07/09/2019
MARIA FERNANDA MARTINEZ-BOCK	07/11/2019
JOSE MARIA MAINOU-SIERRA	07/30/2019
SARAH ASHLEY-MAGUIRE	07/11/2019
RECEIVING PARTY DATA	
Name:	FRESENIUS KABI DEUTSCHLAND GMBH
Street Address:	ELSE-KRÖENER-STRASSE 1
City:	BAD HOMBURG
State/Country:	GERMANY
Postal Code:	61352
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16461616
CORRESPONDENCE DATA	
Fax Number:	(202)595-0560
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(202) 394-3577
Email:	docket@hyltonrodiclaw.com
Correspondent Name:	HYLTON-RODIC LAW PLLC
Address Line 1:	700 12TH STREET NW, SUITE 7
Address Line 4:	WASHINGTON, D.C. 20005
ATTORNEY DOCKET NUMBER:	FKP-023US01
NAME OF SUBMITTER:	DR. KEISHA HYLTON-RODIC
SIGNATURE:	/KEISHA HYLTON-RODIC/
DATE SIGNED:	02/10/2022
Total Attachments: 12	

source=2022-02-11_FKP-023US01_Recorded_Assignment#page1.tif
source=2022-02-11_FKP-023US01_Recorded_Assignment#page2.tif
source=2022-02-11_FKP-023US01_Recorded_Assignment#page3.tif
source=2022-02-11_FKP-023US01_Recorded_Assignment#page4.tif
source=2022-02-11_FKP-023US01_Recorded_Assignment#page5.tif
source=2022-02-11_FKP-023US01_Recorded_Assignment#page6.tif
source=2022-02-11_FKP-023US01_Recorded_Assignment#page7.tif
source=2022-02-11_FKP-023US01_Recorded_Assignment#page8.tif
source=2022-02-11_FKP-023US01_Recorded_Assignment#page9.tif
source=2022-02-11_FKP-023US01_Recorded_Assignment#page10.tif
source=2022-02-11_FKP-023US01_Recorded_Assignment#page11.tif
source=2022-02-11_FKP-023US01_Recorded_Assignment#page12.tif

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent, or other good and valuable consideration paid to the undersigned inventors: **Edmundo BRITO DE LA FUENTE; Ericka PESTANA; Stephanie REICHART; Maria Fernanda MARTINEZ-BOCK; Jose MARIA MAINOU-SIERRA; and Sarah ASHLEY-MAGUIRE**; hereby sell and assign to **Fresenius Kabi Deutschland GmbH**, a corporation, whose mailing address is *Else-Kröner-Strasse 1, 61352 Bad Homburg, Germany* (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100),

- (a) in the invention(s) known as **NUTRITIONAL COMPOSITION FOR USE IN THERAPY OF PATIENTS WITH SARCOPENIA AND/OR FRAILTY OR PRE-SARCOPENIC AND/OR PRE-FRAIL PATIENTS** for which an international patent application was filed on PCT/EP2017/079392 (also known as International Application No. November 16, 2017), which claims priority to EP 16199106.2, filed on November 16, 2016, in any and all non-provisional and/or U.S. National Stage patent applications therefrom, in any and all Letters Patent(s) granted from such applications,
- (b) in any and all applications that claim the benefit of the patent applications listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent applications or Letters Patents therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and
- (c) in any and all inventions described in the patent applications listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent applications, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent applications, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the above-referenced application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination, or corresponding application(s) thereof and also to

execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any interference, derivation proceeding, USPTO post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference, derivation proceeding, USPTO post-grant proceeding, or patent enforcement action.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with USPTO Customer Number 130133, the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her names.

Date: 9th July 2019 Signature of Inventor: Edmundo Brito de la Fuente
Edmundo BRITO DE LA FUENTE

Date: _____ Signature of Inventor: _____
Ericka Pestana

Date: _____ Signature of Inventor: _____
Stephanie REICHART

Date: _____ Signature of Inventor: _____
Maria Fernanda MARTINEZ-BOCK

Date: _____ Signature of Inventor: _____
Jose Maria Mainou-Sierra

Date: _____ Signature of Inventor: _____
Sarah ASHLEY-MAGUIRE

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent, or other good and valuable consideration paid to the undersigned inventors: **Edmundo BRITO DE LA FUENTE; Ericka PESTANA; Stephanie REICHART; Maria Fernanda MARTINEZ-BOCK; Jose MARIA MAINOU-SIERRA; and Sarah ASHLEY-MAGUIRE**; hereby sell and assign to **Fresenius Kabi Deutschland GmbH**, a corporation, whose mailing address is *Else-Kröener-Strasse 1, 61352 Bad Homburg, Germany* (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100),

- (a) in the invention(s) known as **NUTRITIONAL COMPOSITION FOR USE IN THERAPY OF PATIENTS WITH SARCOPENIA AND/OR FRAILTY OR PRE-SARCOPENIC AND/OR PRE-FRAIL PATIENTS** for which an international patent application was filed on PCT/EP2017/079392 (also known as International Application No. November 16, 2017), which claims priority to EP 16199106.2, filed on November 16, 2016, in any and all non-provisional and/or U.S. National Stage patent applications therefrom, in any and all Letters Patent(s) granted from such applications,
- (b) in any and all applications that claim the benefit of the patent applications listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent applications or Letters Patents therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and
- (c) in any and all inventions described in the patent applications listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent applications, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent applications, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the above-referenced application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination, or corresponding application(s) thereof and also to

execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any interference, derivation proceeding, USPTO post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference, derivation proceeding, USPTO post-grant proceeding, or patent enforcement action.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with USPTO Customer Number 130133, the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her names.

Date: _____ Signature of Inventor: _____

Edmundo BRITO DE LA FUENTE

Date: July 18, 2019 Signature of Inventor: _____

Ericka Pestana

Date: _____ Signature of Inventor: _____

Stephanie REICHART

Date: _____ Signature of Inventor: _____

Maria Fernanda MARTINEZ-BOCK

Date: _____ Signature of Inventor: _____

Jose Maria Mainou-Sierra

Date: _____ Signature of Inventor: _____

Sarah ASHLEY-MAGUIRE

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent, or other good and valuable consideration paid to the undersigned inventors: **Edmundo BRITO DE LA FUENTE; Ericka PESTANA; Stephanie REICHART; Maria Fernanda MARTINEZ-BOCK; Jose MARIA MAINOU-SIERRA; and Sarah ASHLEY-MAGUIRE**; hereby sell and assign to **Fresenius Kabi Deutschland GmbH**, a corporation, whose mailing address is *Else-Kröener-Strasse 1, 61352 Bad Homburg, Germany* (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100),

- (a) in the invention(s) known as **NUTRITIONAL COMPOSITION FOR USE IN THERAPY OF PATIENTS WITH SARCOPENIA AND/OR FRAILTY OR PRE-SARCOPENIC AND/OR PRE-FRAIL PATIENTS** for which an international patent application was filed on PCT/EP2017/079392 (also known as International Application No. November 16, 2017), which claims priority to EP 16199106.2, filed on November 16, 2016, in any and all non-provisional and/or U.S. National Stage patent applications therefrom, in any and all Letters Patent(s) granted from such applications,
- (b) in any and all applications that claim the benefit of the patent applications listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent applications or Letters Patents therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and
- (c) in any and all inventions described in the patent applications listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent applications, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent applications, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the above-referenced application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination, or corresponding application(s) thereof and also to

The undersigned inventors agree to execute all papers necessary in connection with any interference, derivation proceeding, USPTO post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference, derivation proceeding, USPTO post-grant proceeding, or patent enforcement action.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with USPTO Customer Number 130133, the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her names.

Date: _____ Signature of Inventor: _____

Edmundo BRITO DE LA FUENTE

Date: _____ Signature of Inventor: _____

Ericka Pestana

Date: _____ Signature of Inventor: _____

Sarah ASHLEY-MAGUIRE

Date: _____ Signature of Inventor: _____

Jose Maria Mainou-Sierra

Date: _____ Signature of Inventor: _____

Maria Fernanda MARTINEZ-BOCK

Date: 9 July 2019 Signature of Inventor: S. Reichart

Stephanie REICHART

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent, or other good and valuable consideration paid to the undersigned inventors: **Edmundo BRITO DE LA FUENTE; Ericka PESTANA; Stephanie REICHART; Maria Fernanda MARTINEZ-BOCK; Jose MARIA MAINOU-SIERRA; and Sarah ASHLEY-MAGUIRE**; hereby sell and assign to **Fresenius Kabi Deutschland GmbH**, a corporation, whose mailing address is *Else-Kröner-Strasse 1, 61352 Bad Homburg, Germany* (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100),

- (a) in the invention(s) known as **NUTRITIONAL COMPOSITION FOR USE IN THERAPY OF PATIENTS WITH SARCOPENIA AND/OR FRAILTY OR PRE-SARCOPENIC AND/OR PRE-FRAIL PATIENTS** for which an international patent application was filed on PCT/EP2017/079392 (also known as International Application No. November 16, 2017), which claims priority to EP 16199106.2, filed on November 16, 2016, in any and all non-provisional and/or U.S. National Stage patent applications therefrom, in any and all Letters Patent(s) granted from such applications,
- (b) in any and all applications that claim the benefit of the patent applications listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent applications or Letters Patents therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and
- (c) in any and all inventions described in the patent applications listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent applications, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent applications, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the above-referenced application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination, or corresponding application(s) thereof and also to

execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any interference, derivation proceeding, USPTO post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference, derivation proceeding, USPTO post-grant proceeding, or patent enforcement action.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with USPTO Customer Number 130133, the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her names.

Date: _____ Signature of Inventor: _____

Edmundo BRITO DE LA FUENTE

Date: _____ Signature of Inventor: _____

Ericka Pestana

Date: _____ Signature of Inventor: _____

Stephanie REICHART

Date: 11. July 2019 Signature of Inventor: Maria Fernanda Martinez Bock

Maria Fernanda MARTINEZ-BOCK

Date: _____ Signature of Inventor: _____

Jose Maria Mainou-Sierra

Date: _____ Signature of Inventor: _____

Sarah ASHLEY-MAGUIRE

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent, or other good and valuable consideration paid to the undersigned inventors: **Edmundo BRITO DE LA FUENTE; Ericka PESTANA; Stephanie REICHART; Maria Fernanda MARTINEZ-BOCK; Jose MARIA MAINOU-SIERRA; and Sarah ASHLEY-MAGUIRE**; hereby sell and assign to **Fresenius Kabi Deutschland GmbH**, a corporation, whose mailing address is *Else-Kröener-Strasse 1, 61352 Bad Homburg, Germany* (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100),

- (a) in the invention(s) known as **NUTRITIONAL COMPOSITION FOR USE IN THERAPY OF PATIENTS WITH SARCOPENIA AND/OR FRAILTY OR PRE-SARCOPENIC AND/OR PRE-FRAIL PATIENTS** for which an international patent application was filed on PCT/EP2017/079392 (also known as International Application No. November 16, 2017), which claims priority to EP 16199106.2, filed on November 16, 2016, in any and all non-provisional and/or U.S. National Stage patent applications therefrom, in any and all Letters Patent(s) granted from such applications,
- (b) in any and all applications that claim the benefit of the patent applications listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent applications or Letters Patents therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and
- (c) in any and all inventions described in the patent applications listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent applications, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent applications, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the above-referenced application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination, or corresponding application(s) thereof and also to

execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any interference, derivation proceeding, USPTO post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference, derivation proceeding, USPTO post-grant proceeding, or patent enforcement action.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with USPTO Customer Number 130133, the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her names.

Date: _____ Signature of Inventor: _____

Edmundo BRITO DE LA FUENTE

Date: _____ Signature of Inventor: _____

Ericka Pestana

Date: _____ Signature of Inventor: _____

Stephanie REICHART

Date: _____ Signature of Inventor: _____

Maria Fernanda MARTINEZ-BOCK

Date: 30 July 2015 Signature of Inventor: _____

Jose Maria Mainou-Sierra

Date: _____ Signature of Inventor: _____

Sarah ASHLEY-MAGUIRE

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent, or other good and valuable consideration paid to the undersigned inventors: Edmundo BRITO DE LA FUENTE; Ericka PESTANA; Stephanie REICHART; Maria Fernanda MARTINEZ-BOCK; Jose MARIA MAINOU-SIERRA; and Sarah ASHLEY-MAGUIRE; hereby sell and assign to Fresenius Kabi Deutschland GmbH, a corporation, whose mailing address is *Else-Kröener-Strasse 1, 61352 Bad Homburg, Germany* (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100),

- (a) in the invention(s) known as **NUTRITIONAL COMPOSITION FOR USE IN THERAPY OF PATIENTS WITH SARCOPENIA AND/OR FRAILTY OR PRE-SARCOPENIC AND/OR PRE-FRAIL PATIENTS** for which an international patent application was filed on PCT/EP2017/079392 (also known as International Application No. November 16, 2017), which claims priority to EP 16199106.2, filed on November 16, 2016, in any and all non-provisional and/or U.S. National Stage patent applications therefrom, in any and all Letters Patent(s) granted from such applications,
- (b) in any and all applications that claim the benefit of the patent applications listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent applications or Letters Patents therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and
- (c) in any and all inventions described in the patent applications listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent applications, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent applications, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the above-referenced application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination, or corresponding application(s) thereof and also to

execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any interference, derivation proceeding, USPTO post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference, derivation proceeding, USPTO post-grant proceeding, or patent enforcement action.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with USPTO Customer Number 130133, the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her names.

Date: _____ Signature of Inventor: _____

Edmundo BRITO DE LA FUENTE

Date: _____ Signature of Inventor: _____

Ericka Pestana

Date: _____ Signature of Inventor: _____

Stephanie REICHART

Date: _____ Signature of Inventor: _____

Maria Fernanda MARTINEZ-BOCK

Date: _____ Signature of Inventor: _____

Jose Maria Mainou-Sierra

Date: 11/07/19 Signature of Inventor: 

Sarah ASHLEY-MAGUIRE